Sema vs Tirz vs Retatrutide — picking your incretin

This is a framework for thinking through that decision honestly.

Start with what these compounds share. They all work through incretin receptor signaling — hormonal pathways that originate in the gut and regulate blood sugar, appetite, gastric emptying, and a constellation of downstream metabolic effects. The GLP-1 receptor, when activated, does several things at once: it signals the pancreas to release insulin in response to glucose, it tells the hypothalamus you're full, it slows the rate at which your stomach empties, and it appears to reduce the reward salience of food at the neural level. People who take GLP-1 receptor agonists often describe not just eating less but wanting to eat less — the psychological pull of food quiets in a way that calorie restriction alone rarely produces. That's the foundational mechanism all three compounds share, at least in part.

Where they diverge is in which receptors they add to that foundation.

Semaglutide is a GLP-1 receptor agonist — full stop. It's the monoagonist in this comparison, working entirely through the GLP-1 pathway with no additional receptor activity. This is not a limitation in the pejorative sense; it's a well-characterized, well-understood mechanism that has been studied in large, well-designed trials over many years. The STEP trials for the weight management indication showed a mean body weight reduction of approximately 15% at maximum dose over 68 weeks, with meaningful variance around that number depending on dose achieved, adherence, and individual response. The SUSTAIN-6 trial and LEADER trial established cardiovascular outcome data for semaglutide in people with type 2 diabetes and high cardiovascular risk — this is what clinicians mean when they say semaglutide has "CVOT evidence." It has. Solid, peer-reviewed, widely cited cardiovascular outcome trial data. The FLOW trial, published more recently, added renal outcomes data, demonstrating meaningful reduction in kidney disease progression in people with type 2 diabetes and chronic kidney disease. No other compound in this class has that depth of cardiovascular and renal evidence yet.

Approved as Ozempic for type 2 diabetes and as Wegovy for chronic weight management, semaglutide is the established choice in the most straightforward sense: it has the longest clinical track record, the broadest evidence base, the most established insurance coverage pathway for its approved indications, and the most predictable access. The compounded semaglutide landscape shifted significantly in 2024 and 2025 as the FDA navigated shortage designations, and that regulatory situation continues to evolve — your prescribing provider is the right resource for current access realities rather than anything written here.

Tirzepatide adds a second receptor to the picture. It's a dual GLP-1 and GIP receptor agonist — GIP being glucose-dependent insulinotropic polypeptide, another incretin that was for years considered a less interesting cousin of GLP-1 before the tirzepatide data complicated that picture. The theoretical concern about adding GIP activity was that GIP had been shown in some research to promote fat storage rather than fat loss. What happened in the SURMOUNT trials was the opposite: tirzepatide produced mean weight reductions of approximately 20 to 22% at maximum dose, meaningfully higher than semaglutide's ~15% in comparative context. Why? The honest answer is that the full mechanism isn't settled. GIP agonism may enhance GLP-1 receptor signaling effects. It may have separate adipose tissue effects that are more complex than the early fat-storage hypothesis suggested. It may matter that tirzepatide is a single molecule engaging two receptors rather than two separate drugs — the pharmacology of that distinction is still being characterized.

The glucose effects with tirzepatide are also significant. In the SURPASS trials in type 2 diabetes, tirzepatide demonstrated HbA1c reductions that compared favorably with semaglutide, and the body composition improvements in people with diabetes were substantial. Approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, tirzepatide now has its own cardiovascular outcome trial data emerging — the SURMOUNT-MMO trial is ongoing and will eventually tell us more about hard cardiovascular endpoints. For now, the cardiovascular and renal evidence is less comprehensive than what semaglutide has accumulated over a longer approval timeline. That's not a knock on tirzepatide; it's an acknowledgment that evidence takes time to accumulate and semaglutide had a head start.

GI tolerability is a frequent point of comparison between the two, and the picture here is nuanced. Both cause nausea, particularly at dose escalation, and both can cause vomiting, diarrhea, and constipation — the GI side effect profile is a feature of the class as much as any individual drug. Some clinical observers and patient-reported data suggest tirzepatide may be somewhat better tolerated on a per-dose basis, but direct head-to-head tolerability comparisons are difficult because dosing schedules and titration protocols differ. What can be said with confidence is that neither drug is free of GI side effects, that those effects are most prominent during dose escalation, and that they typically decrease with maintained dosing. Individual tolerance varies enough that it's not useful to state categorically that one is easier than the other.

Insurance coverage differences are real and consequential. Semaglutide for type 2 diabetes and weight management has been on the market longer and has worked its way into more formularies, though coverage for the weight management indication specifically is inconsistent across payers. Tirzepatide is following a similar trajectory but with a shorter history. This is not a medical reason to choose one over the other, but it is a practical reality that affects access for many people, and it belongs in an honest framework.

Retatrutide is neither approved nor available through conventional prescribing at the time of this writing. It is an investigational triple agonist — GLP-1, GIP, and glucagon receptor agonist — and the Phase II data, published in the New England Journal of Medicine in 2023, reported a mean weight reduction of approximately 24% at the highest dose over 48 weeks. That number drew significant attention. The addition of glucagon receptor activity is what distinguishes retatrutide from tirzepatide mechanistically: glucagon, in this context, is being recruited not for its blood-sugar-raising effects (which require the right fasting conditions) but for its thermogenic and lipolytic effects — glucagon receptor activation promotes energy expenditure and fat mobilization in ways that GLP-1 and GIP alone don't. At least, that's the mechanism hypothesis. Phase III trials are ongoing. Retatrutide does not have FDA approval. It is not commercially available. Whatever anyone on the internet is calling "retatrutide" that you can purchase today is not the compound that produced those Phase II results in a controlled, manufacturer-supervised clinical trial context.

The glucagon receptor addition also introduces considerations that require careful clinical evaluation. Glucagon raises blood glucose under fasting conditions — the full safety profile of triple agonism in people with type 2 diabetes, and at the doses that produce maximum weight loss, requires the Phase III data that is still being generated. Retatrutide's safety profile is less characterized than either of the two approved options, which is the expected reality of a compound still in development. This isn't a reason to dismiss it — the efficacy signal is real and meaningful — but it's a reason to hold the 24% figure in the right context: this is a Phase II result from a relatively small trial, not a definitive efficacy number from a Phase III program with the statistical power and duration to establish it definitively.

So how do you actually pick?

If your priority is maximum weight reduction and retatrutide becomes available through a legitimate, FDA-approved pathway, the Phase III data will determine whether that early efficacy signal holds. Until then, it is not an option in any practical sense. If your priority is maximum weight reduction right now with an approved, available compound, tirzepatide has the better efficacy data. If you have a history of cardiovascular disease or significant cardiovascular risk and you want the compound with the strongest hard outcomes evidence, semaglutide's CVOT track record is the most established, and its renal data from FLOW is clinically meaningful for people with diabetes and kidney disease. If insurance access is a limiting factor, semaglutide's longer approval history and formulary presence may make it more accessible. If you have type 2 diabetes and the primary goal is glucose management alongside weight, all three are researched for that indication — tirzepatide's dual mechanism may have an edge in specific diabetes contexts, but this is a conversation for your prescribing provider with your labs in front of them.

What this decision shouldn't be is a chase for the highest number. A mean 22% weight reduction in SURMOUNT doesn't mean you will lose 22% of your body weight. Mean weight loss figures include the full distribution of responders and non-responders, people who stayed at maximum dose and people who didn't, people who adhered to the diet protocol and people who didn't. Individual response to GLP-1 axis compounds is genuinely variable in ways that the current evidence cannot fully predict. Genetic factors, baseline insulin resistance, gut hormone levels, dietary context, and the specific characteristics of how your body processes incretin signaling all matter.

The honest framework is this: evaluate your medical situation — cardiovascular history, renal function, diabetes status, current weight, prior GI issues, insurance situation — with a prescribing provider who has reviewed your labs and your history. Then match the compound to the situation rather than to the clinical trial headline. The drug that fits your clinical profile and that you can actually access and afford and tolerate is the right drug for you. The one that produced the highest average weight loss in a trial is interesting information, and it belongs in the conversation, but it doesn't belong at the top of the decision framework in isolation from everything else.